Literature DB >> 31931021

Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.

Amedeo Sciarra1, Young Nyun Park2, Christine Sempoux3.   

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma showing variable degrees of differentiation toward hepatocellular and cholangiocellular carcinoma. Its great heterogeneity in term of morphology, immunophenotype, molecular, radiological and clinical features represents a challenge still to overcome. The multidisciplinary 2018 International Consensus on the nomenclature of cHCC-CCA allowed to define key issues of this entity. Here we review the historical controversies of cHCC-CCA, resume the key elements of the 2018 consensus, now incorporated in the 2019 WHO classification, and propose a short survival guide to help surgical pathologists facing cHCC-CCA in their routine workup.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Cholangiocarcinoma; Cholangiolocarcinoma; Combined hepatocellular-cholangiocarcinoma; Hepatocellular carcinoma; Primary liver carcinoma

Year:  2020        PMID: 31931021     DOI: 10.1016/j.humpath.2019.11.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.

Authors:  Mustafa Nazzal; Subhayan Sur; Robert Steele; Mousumi Khatun; Tapas Patra; Nancy Phillips; John Long; Ranjit Ray; Ratna B Ray
Journal:  Hepatology       Date:  2020-08       Impact factor: 17.425

2.  Evaluation of short- and medium-term efficacy and complications of ultrasound-guided ablation for small liver cancer.

Authors:  Hua Zhong; Rong Hu; Yun-Shan Jiang
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

3.  Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study.

Authors:  Zhen Yang; Guangjun Shi
Journal:  Cancer Med       Date:  2021-12-04       Impact factor: 4.452

4.  A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.

Authors:  Naoto Saito; Takeshi Hatanaka; Sachi Nakano; Yoichi Hazama; Sachiko Yoshida; Yoko Hachisu; Yoshiki Tanaka; Teruo Yoshinaga; Kenji Kashiwabara; Norio Kubo; Yasuo Hosouchi; Hiroki Tojima; Satoru Kakizaki; Toshio Uraoka
Journal:  Clin Case Rep       Date:  2022-07-25

Review 5.  Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.

Authors:  Joon Hyuk Choi; Jae Y Ro
Journal:  Biomedicines       Date:  2022-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.